LA01

LA01 is a potent and highly selective monoclonal antibody targeting the activin type IIA receptor (ActRIIA), currently under investigation for the treatment of obesity and muscle-wasting conditions. Developed by Laekna Therapeutics, LA01 binds to ActRIIA with a dissociation constant (KD) of 67 pM and an IC50 of 0.2 nM, demonstrating no cross-reactivity with the closely related ActRIIB receptor. The antibody's mechanism of action involves blocking the inhibitory effects of ligands such as GDF8 (myostatin) and activin A on muscle growth and differentiation. Preclinical data presented at the ADA 2026 meeting indicates that LA01 can completely prevent GDF8-induced myotube atrophy and significantly increase myotube number, width, and differentiation index in human myoblast models. Its efficacy is comparable to the dual ActRIIA/IIB inhibitor bimagrumab, but its selective targeting of ActRIIA is intended to provide a more precise therapeutic approach for preserving muscle mass, particularly as a co-therapy in obesity management.